Additional studies have described cancer immunocytokine therapy incorporating tissue factor, IL-4, IL-3, granulocyte colony-stimulating factor (G-CSF), IL-1β, IL-6, IL-13, IL-17, IL-7, vascular endothelial growth factor (VEGF), C-C motif chemokine ligand 21 (CCL21), and 4-1BBL [95,112,113,114,115,116,117,118,119,120,121,122,123,124]. This evidence concerns the gene CCL21 and cancer.